Published in CA Cancer J Clin on February 08, 2011
Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One (2013) 4.31
Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer. Cell (2015) 1.84
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer (2012) 1.42
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol (2012) 1.18
MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci (2013) 1.13
MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget (2015) 1.06
A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Curr Cancer Drug Targets (2011) 1.03
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03
Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res (2012) 1.02
Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer (2012) 1.02
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther (2012) 1.01
Genetic susceptibility to lung cancer--light at the end of the tunnel? Carcinogenesis (2013) 1.00
The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther (2015) 0.98
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med (2013) 0.97
Alveolar type II cells possess the capability of initiating lung tumor development. PLoS One (2012) 0.96
miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4. J Biol Chem (2014) 0.93
Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin Lung Cancer (2013) 0.93
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med (2013) 0.92
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist (2013) 0.91
Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin. Int J Mol Sci (2013) 0.91
Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung. Br J Cancer (2011) 0.90
microRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells. Oncol Lett (2015) 0.90
Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells. BMB Rep (2014) 0.90
TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res (2013) 0.90
GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One (2014) 0.89
Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. Onco Targets Ther (2013) 0.88
miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. J Cancer Res Clin Oncol (2012) 0.88
A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci Rep (2013) 0.88
Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis. PLoS One (2013) 0.87
Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues. Cancer Cell Int (2015) 0.87
Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS One (2014) 0.87
Mimulone-induced autophagy through p53-mediated AMPK/mTOR pathway increases caspase-mediated apoptotic cell death in A549 human lung cancer cells. PLoS One (2014) 0.86
Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci (2015) 0.85
Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci (2012) 0.85
MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27. Int J Clin Exp Med (2015) 0.85
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer. Biomed Res Int (2014) 0.84
Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer. World J Surg Oncol (2015) 0.84
The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS One (2015) 0.84
Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs. Oncotarget (2014) 0.83
The associations between two vital GSTs genetic polymorphisms and lung cancer risk in the Chinese population: evidence from 71 studies. PLoS One (2014) 0.83
Protein Arginine Methyltransferases (PRMTs): promising targets for the treatment of pulmonary disorders. Int J Mol Sci (2012) 0.82
Palliative care in patients with lung cancer. Contemp Oncol (Pozn) (2013) 0.82
Prediction of Clinical Outcome for All Stages and Multiple Cell Types of Non-small Cell Lung Cancer in Five Countries Using Lung Cancer Prognostic Index. EBioMedicine (2014) 0.82
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol (2014) 0.82
A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther (2014) 0.81
Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo. J Cancer Res Clin Oncol (2014) 0.81
A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Per Med (2012) 0.81
Outcome of surgical resection for brain metastases and radical treatment of the primary tumor in Chinese non-small-cell lung cancer patients. Onco Targets Ther (2015) 0.81
Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells. Br J Pharmacol (2012) 0.81
Wilms' tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway. Cancer Cell Int (2013) 0.81
miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett (2016) 0.80
A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1. PLoS One (2012) 0.80
Upregulation of miR-1280 expression in non-small cell lung cancer tissues. Chin Med J (Engl) (2015) 0.78
Role of autophagy in the ω-3 long chain polyunsaturated fatty acid-induced death of lung cancer A549 cells. Oncol Lett (2015) 0.78
MiR-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting PAK1. Int J Clin Exp Med (2015) 0.78
Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer (2015) 0.77
TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers. PLoS One (2016) 0.77
PLCε signaling in cancer. J Cancer Res Clin Oncol (2015) 0.77
Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer. BMC Cancer (2016) 0.77
Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci Appl (2015) 0.77
Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain). BMC Health Serv Res (2015) 0.76
Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer. Oncotarget (2015) 0.76
LncRNA16 is a potential biomarker for diagnosis of early-stage lung cancer that promotes cell proliferation by regulating the cell cycle. Oncotarget (2017) 0.76
Diagnostic value of protein chips constructed by lung-cancer-associated markers selected by the T7 phage display library. Thorac Cancer (2015) 0.76
Aurora-A is a novel predictor of poor prognosis in patients with resected lung adenocarcinoma. Chin J Cancer Res (2014) 0.76
Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model. Cancer (2016) 0.75
PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells. Exp Biol Med (Maywood) (2016) 0.75
Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. PLoS One (2015) 0.75
Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. PLoS One (2016) 0.75
Chromosomal and Genetic Analysis of a Human Lung Adenocarcinoma Cell Line OM. Chin Med J (Engl) (2016) 0.75
Differential effects of MTSS1 on invasion and proliferation in subtypes of non-small cell lung cancer cells. Exp Ther Med (2016) 0.75
Dejection and self-assessment of quality of life in patients with lung cancer subjected to palliative care. Contemp Oncol (Pozn) (2016) 0.75
Tazarotene-induced gene 2 is associated with poor survival in non-small cell lung cancer. Oncol Lett (2016) 0.75
Pre-diagnostic cruciferous vegetables intake and lung cancer survival among Chinese women. Sci Rep (2015) 0.75
Amide-linked local anesthetics induce apoptosis in human non-small cell lung cancer. J Thorac Dis (2016) 0.75
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. Oncotarget (2016) 0.75
Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol (2014) 0.75
The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis. Sci Rep (2017) 0.75
MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. Oncotarget (2017) 0.75
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. J Neurooncol (2017) 0.75
The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Oncotarget (2017) 0.75
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol (2006) 1.78
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther (2007) 1.71
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 1.47
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem (2010) 1.40
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol (2011) 1.38
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer (2012) 1.33
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res (2004) 1.30
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther (2008) 1.29
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol Ther (2006) 1.27
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res (2008) 1.26
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res (2008) 1.25
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res (2006) 1.24
Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer (2004) 1.24
Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene (2004) 1.21
Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev (2003) 1.21
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther (2009) 1.21
HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol (2012) 1.21
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One (2011) 1.19
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther (2013) 1.19
Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol (2004) 1.18
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol (2012) 1.18
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia (2010) 1.16
Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer (2004) 1.16
Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res (2005) 1.15
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther (2011) 1.14
Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer (2013) 1.13
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci U S A (2011) 1.12
Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res (2005) 1.12
Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One (2010) 1.11
Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther (2008) 1.10
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem (2007) 1.09
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia (2010) 1.09
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun (2013) 1.08
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem (2010) 1.08
Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol Cancer Ther (2011) 1.08
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther (2007) 1.07
ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. J Biol Chem (2010) 1.07
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer (2008) 1.06
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book (2013) 1.06
Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res (2006) 1.06
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer (2014) 1.05